問題 › 戦略が機能しているかを判断できない › ヘルステックおよびデジタルヘルス
誤り得ない戦略は検証できません。デジタルヘルスで書かれる戦略の多くは、誤り得ない形で書かれています。 デジタルヘルス企業には特有の制約があります。成果リスクが、企業がそれを担えるかを学習できる速度よりも速く引き受けられるという点です。12カ月の測定期間に対し11カ月の販売サイクルというものです。これが価格設定されない限り、成果連動型収益シェアは誰も原因を特定できない理由で動き続け、先行指標に関する議論は意見の域を出ないままです。
誤り得ない戦略は検証できません。デジタルヘルスで書かれる戦略の多くは、誤り得ない形で書かれています。 デジタルヘルス企業には特有の制約があります。成果リスクが、企業がそれを担えるかを学習できる速度よりも速く引き受けられるという点です。12カ月の測定期間に対し11カ月の販売サイクルというものです。これが価格設定されない限り、成果連動型収益シェアは誰も原因を特定できない理由で動き続け、先行指標に関する議論は意見の域を出ないままです。
戦略を評価できない通常の理由は、失敗し得る形で述べられていないことです。成果を帰属させる拡大や成果連動型収益シェアの拡大といった主張は、それを否定する観察を生まず、結果にかかわらず無期限に存続します。
検証可能な戦略は仕組みを明示します。このエンゲージメント率の変化がこの日までに成果連動型収益シェアのこの変化を生む、とし、その仕組みが機能していないことを示す観察を述べます。この後半が、計画をCEOやCFOが管理できるものに変えます。
もう一つの頻出原因は遅れです。戦略は報告サイクルより長い期間で機能するため、正直な対応はエンゲージメント率のような先行指標を特定し、それが事前にどうあるべきかを述べることです。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ 現在の契約が実行不可能であることを証明するエンゲージメント率や成果連動型収益シェアを誰も挙げられません。
✓ 週次更新は完了した導入と登録メンバーを挙げますが、PMPMや粗利益率の変化とは結びつきません。
✓ CEOとCFOは成果リスクが持続可能かどうかの結論が異なり、同じ数字からそれを解決できません。
通常、事態を悪化させる対応です。 完了した活動に関する報告を増やすことです。数字の量は増えますが、成果連動型収益シェアやロゴの解約との結びつきは検証不能のままです。
It is for you if you run or finance a digital health company and the strategy has no failure condition written anywhere. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on デジタルヘルス企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 独自のEFF Methodology, one of 29 engagements the platform runs. For デジタルヘルス企業 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
約束する成果ではなく、それが依存する仕組みです。成果は遅れますが、仕組みは早く動き、因果関係の主張が成り立つかを早く知らせます。
開始前に決め、仕組みの自然な周期に結びつけます。後で決めると、結果に合うよう期間が選ばれることが確実です。
それは通常、戦略がきれいな検証を生むほど具体的に述べられていない兆候です。一つの数字で議論を決着できるまで絞り込みます。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית